|
Gene: PPP5C |
Gene summary for PPP5C |
Gene summary. |
Gene information | Species | Human | Gene symbol | PPP5C | Gene ID | 5536 |
Gene name | protein phosphatase 5 catalytic subunit | |
Gene Alias | PP5 | |
Cytomap | 19q13.32 | |
Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | A0A024R0Q7 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
5536 | PPP5C | LZE2T | Human | Esophagus | ESCC | 6.38e-04 | 5.18e-01 | 0.082 |
5536 | PPP5C | LZE4T | Human | Esophagus | ESCC | 2.24e-07 | 2.83e-01 | 0.0811 |
5536 | PPP5C | LZE7T | Human | Esophagus | ESCC | 4.41e-07 | 4.77e-01 | 0.0667 |
5536 | PPP5C | LZE8T | Human | Esophagus | ESCC | 2.57e-07 | 2.94e-01 | 0.067 |
5536 | PPP5C | LZE22D1 | Human | Esophagus | HGIN | 1.39e-05 | 1.94e-01 | 0.0595 |
5536 | PPP5C | LZE22T | Human | Esophagus | ESCC | 1.18e-02 | 3.19e-01 | 0.068 |
5536 | PPP5C | LZE24T | Human | Esophagus | ESCC | 4.29e-12 | 3.05e-01 | 0.0596 |
5536 | PPP5C | LZE6T | Human | Esophagus | ESCC | 4.28e-08 | 4.47e-01 | 0.0845 |
5536 | PPP5C | P1T-E | Human | Esophagus | ESCC | 2.29e-14 | 4.04e-01 | 0.0875 |
5536 | PPP5C | P2T-E | Human | Esophagus | ESCC | 1.19e-26 | 4.91e-01 | 0.1177 |
5536 | PPP5C | P4T-E | Human | Esophagus | ESCC | 2.01e-22 | 5.76e-01 | 0.1323 |
5536 | PPP5C | P5T-E | Human | Esophagus | ESCC | 2.48e-21 | 4.99e-01 | 0.1327 |
5536 | PPP5C | P8T-E | Human | Esophagus | ESCC | 5.24e-57 | 1.08e+00 | 0.0889 |
5536 | PPP5C | P9T-E | Human | Esophagus | ESCC | 4.08e-14 | 3.01e-01 | 0.1131 |
5536 | PPP5C | P10T-E | Human | Esophagus | ESCC | 2.87e-38 | 7.80e-01 | 0.116 |
5536 | PPP5C | P11T-E | Human | Esophagus | ESCC | 4.52e-16 | 6.19e-01 | 0.1426 |
5536 | PPP5C | P12T-E | Human | Esophagus | ESCC | 2.62e-35 | 6.43e-01 | 0.1122 |
5536 | PPP5C | P15T-E | Human | Esophagus | ESCC | 2.33e-37 | 7.94e-01 | 0.1149 |
5536 | PPP5C | P16T-E | Human | Esophagus | ESCC | 1.45e-24 | 4.30e-01 | 0.1153 |
5536 | PPP5C | P17T-E | Human | Esophagus | ESCC | 4.02e-16 | 6.60e-01 | 0.1278 |
Page: 1 2 3 4 5 6 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003314316 | Thyroid | ATC | regulation of intracellular steroid hormone receptor signaling pathway | 43/6293 | 74/18723 | 1.30e-05 | 1.25e-04 | 43 |
GO:001631117 | Thyroid | ATC | dephosphorylation | 179/6293 | 417/18723 | 3.88e-05 | 3.15e-04 | 179 |
GO:190121519 | Thyroid | ATC | negative regulation of neuron death | 97/6293 | 208/18723 | 6.19e-05 | 4.73e-04 | 97 |
GO:000630212 | Thyroid | ATC | double-strand break repair | 110/6293 | 251/18723 | 4.48e-04 | 2.65e-03 | 110 |
GO:007124124 | Thyroid | ATC | cellular response to inorganic substance | 98/6293 | 226/18723 | 1.35e-03 | 7.02e-03 | 98 |
GO:004668632 | Thyroid | ATC | response to cadmium ion | 35/6293 | 68/18723 | 1.76e-03 | 8.71e-03 | 35 |
GO:003195821 | Thyroid | ATC | corticosteroid receptor signaling pathway | 11/6293 | 15/18723 | 1.94e-03 | 9.41e-03 | 11 |
GO:0009755110 | Thyroid | ATC | hormone-mediated signaling pathway | 83/6293 | 190/18723 | 2.34e-03 | 1.09e-02 | 83 |
GO:004292121 | Thyroid | ATC | glucocorticoid receptor signaling pathway | 10/6293 | 14/18723 | 4.31e-03 | 1.80e-02 | 10 |
GO:007026221 | Thyroid | ATC | peptidyl-serine dephosphorylation | 12/6293 | 19/18723 | 7.97e-03 | 3.08e-02 | 12 |
GO:007124823 | Thyroid | ATC | cellular response to metal ion | 82/6293 | 197/18723 | 1.11e-02 | 3.99e-02 | 82 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0401014 | Oral cavity | OSCC | MAPK signaling pathway | 165/3704 | 302/8465 | 7.11e-05 | 2.74e-04 | 1.40e-04 | 165 |
hsa0401015 | Oral cavity | OSCC | MAPK signaling pathway | 165/3704 | 302/8465 | 7.11e-05 | 2.74e-04 | 1.40e-04 | 165 |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PPP5C | SNV | Missense_Mutation | novel | c.1385N>C | p.Ile462Thr | p.I462T | P53041 | protein_coding | deleterious(0) | probably_damaging(0.985) | TCGA-AC-A23C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | chemo | CR |
PPP5C | SNV | Missense_Mutation | novel | c.1100N>A | p.Arg367Gln | p.R367Q | P53041 | protein_coding | tolerated(0.08) | benign(0.116) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PPP5C | SNV | Missense_Mutation | novel | c.435N>C | p.Gln145His | p.Q145H | P53041 | protein_coding | deleterious(0.01) | possibly_damaging(0.868) | TCGA-BH-A0B6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PPP5C | insertion | In_Frame_Ins | novel | c.542_543insCCTCTGCCTGTGTTCCAGGGCGCTCCATCCACAGCCCAAAGC | p.Leu181_Glu182insLeuCysLeuCysSerArgAlaLeuHisProGlnProLysAla | p.L181_E182insLCLCSRALHPQPKA | P53041 | protein_coding | TCGA-BH-A0B8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD | ||
PPP5C | deletion | Frame_Shift_Del | novel | c.1300delN | p.Tyr434ThrfsTer63 | p.Y434Tfs*63 | P53041 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
PPP5C | SNV | Missense_Mutation | novel | c.1408N>T | p.Arg470Trp | p.R470W | P53041 | protein_coding | deleterious(0) | benign(0.336) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
PPP5C | SNV | Missense_Mutation | c.782N>T | p.Ser261Leu | p.S261L | P53041 | protein_coding | deleterious(0) | possibly_damaging(0.828) | TCGA-EK-A2RA-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD | |
PPP5C | SNV | Missense_Mutation | c.76N>G | p.Lys26Glu | p.K26E | P53041 | protein_coding | tolerated(1) | benign(0) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
PPP5C | SNV | Missense_Mutation | rs749045957 | c.338N>A | p.Arg113Gln | p.R113Q | P53041 | protein_coding | deleterious(0.04) | benign(0.003) | TCGA-IR-A3LL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
PPP5C | SNV | Missense_Mutation | rs778377016 | c.1333N>A | p.Val445Ile | p.V445I | P53041 | protein_coding | tolerated(0.1) | benign(0.093) | TCGA-A6-6781-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | oxaliplatin | SD |
Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |